[Anti-ulcer agent pirenzepine (LS 519)--a tricyclic compound with particular physico-chemical properties (author's transl)]
- PMID: 577153
[Anti-ulcer agent pirenzepine (LS 519)--a tricyclic compound with particular physico-chemical properties (author's transl)]
Abstract
Compound 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one dihydrochloride (pirenzepine, L-S 519) represents a new type of drug in ulcer therapy. It has been selected for broad clinical investigations because of its outstanding pharmacological profile. Pirenzepine is devoid of any central activity despite certain structural similarities in relation to psychotropic tricyclic compounds. The extraordinary pharmacokinetic and pharmacodynamic behaviour of this compound can be easily derived from its inherent physicochemical properties: The inability to pass the blood-brain barrier as well as its inability to activate the unspecific and specific psychotropic receptors is due to thermodynamic factors.
Similar articles
-
[Inhibition of nocturnal acid secretion by pirenzepine (author's transl)].Arzneimittelforschung. 1982;32(3):309-10. Arzneimittelforschung. 1982. PMID: 7044387 Clinical Trial. German.
-
[Mechanism of action of the gastric secretion inhibitor Pirenzepin].Fortschr Med. 1980 Apr 10;98(14):(549-54). Fortschr Med. 1980. PMID: 6892811 German. No abstract available.
-
The pharmacokinetic profile of pirenzepine.Scand J Gastroenterol Suppl. 1979;57:1-6. Scand J Gastroenterol Suppl. 1979. PMID: 295516
-
Agents with tricyclic structures for treating peptic ulcer disease.Clin Pharm. 1983 Sep-Oct;2(5):425-31. Clin Pharm. 1983. PMID: 6354568 Review.
-
Newer drugs in the treatment of peptic ulcer.Trop Gastroenterol. 1985 Oct-Dec;6(4):188-92. Trop Gastroenterol. 1985. PMID: 3913076 Review. No abstract available.
Cited by
-
Relationship of erosive gastritis to the acid secreting area and intestinal metaplasia, and the healing effect of pirenzepine.Gut. 1987 May;28(5):561-5. doi: 10.1136/gut.28.5.561. Gut. 1987. PMID: 3297938 Free PMC article. Clinical Trial.
-
Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man.J Endocrinol Invest. 1982 Jan-Feb;5(1):53-5. doi: 10.1007/BF03350483. J Endocrinol Invest. 1982. PMID: 6808052
-
Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.Drugs. 1985 Aug;30(2):85-126. doi: 10.2165/00003495-198530020-00001. Drugs. 1985. PMID: 3928324 Review.
-
Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine.Br J Pharmacol. 1986 Sep;89(1):83-90. doi: 10.1111/j.1476-5381.1986.tb11123.x. Br J Pharmacol. 1986. PMID: 2432979 Free PMC article.